Research progress of siRNA in reducing serum HBsAg levels in patients with chronic hepatitis B
10.3760/cma.j.issn.1007-3418.2020.02.017
- VernacularTitle:siRNA药物降低慢性乙型肝炎患者血清HBsAg水平的研究进展
- Author:
Jiali PAN
1
;
Xiaoyuan XU
Author Information
1. 北京大学第一医院感染疾病科 100034
- Keywords:
Hepatitis B,chronic;
Hepatitis B surface antigen;
RNA,small Interfering
- From:
Chinese Journal of Hepatology
2020;28(2):179-182
- CountryChina
- Language:Chinese
-
Abstract:
Small interfering RNA (siRNA) is mainly involved in RNA interference for stopping gene translation by targeting and degrading HBV-transcribed mRNA.Targeting and stability in siRNA can be enhanced via chemical modification,combination use and improved delivery system.Clinical studies have identified JNJ-3989 (ARO-HBV) and ARB-1740 as well-tolerated siRNA drugs,which significantly reduce HBsAg levels.This article expounds the main mechanisms of siRNA in inhibiting HBsAg expression,improving target and stability as well as relevant preclinical and clinical studies.
